http://www.aidsmap.com/Vienna-2010-news/page/1446573/ en-gb NAM Publications - 2012 Fri, 25 May 2012 01:33:15 GMT Fri, 25 May 2012 01:33:15 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ Scientists, lawyers and advocates have been able to reduce unwarranted prosecutions of HIV exposure and transmission in three European jurisdictions by employing three distinct approaches, Robert James told the Eighteenth International AIDS Conference in Vienna last week. The conference also heard details of non-disclosure, exposure and transmission cases in the United States, the country in http://www.aidsmap.com/Three-tactics-to-stem-the-tide-of-criminal-prosecutions/page/1498385/ HIV and criminal law Low and theoretical transmission risks Netherlands Switzerland United Kingdom United States Vienna 2010 Roger Pebody http://www.aidsmap.com/page/1498385/ Thu, 29 Jul 2010 17:50:00 GMT In the countries of Eastern Europe and Central Asia, 89% of national government funding for HIV prevention goes on programmes for the general population, although most countries’ epidemics are dominated by injecting drug use, Shona Schonning of the Eurasian Harm Reduction Network told the Eighteenth International AIDS Conference in Vienna last week. She was one of http://www.aidsmap.com/Less-than-10-of-East-European-prevention-spending-is-for-vulnerable-groups/page/1497950/ Epidemiology Injecting drug use Injecting drug users Russian Federation Transmission and prevention Ukraine Vienna 2010 Roger Pebody http://www.aidsmap.com/page/1497950/ Wed, 28 Jul 2010 10:40:00 GMT Two scientific lectures presented at the Eighteenth International AIDS Conference in Vienna last week, demonstrated that drug use in and of itself is linked to increased rates of HIV transmission, giving support for evidence that substitution therapy programmes could help to stem the HIV epidemic. Currently, ten million injecting drug users (IDUs) are living http://www.aidsmap.com/New-studies-strengthen-evidence-that-drug-addiction-is-a-disease-of-the-brain-substitution-therapy-necessary/page/1497490/ East Asia Eastern Europe and Central Asia Injecting drug users South and South-east Asia Vienna 2010 Mara Kardas-Nelson http://www.aidsmap.com/page/1497490/ Tue, 27 Jul 2010 15:00:00 GMT Drug policies based on ideology rather than science are fueling human rights abuses of drug users, according to a panel of experts speaking at last week’s Eighteenth International AIDS Conference which took place in Vienna, Austria. Violations of physical and legal rights coupled with poor outcomes mar many countries' drug treatment programmes, which can include http://www.aidsmap.com/Evidence-based-treatment-of-drug-users-needed-to-strengthen-human-rights-stem-drug-use-and-halt-the-HIV-epidemic/page/1497482/ Eastern Europe and Central Asia Injecting drug users South and South-east Asia Vienna 2010 Mara Kardas-Nelson http://www.aidsmap.com/page/1497482/ Tue, 27 Jul 2010 14:50:00 GMT At the International AIDS Conference in Vienna, a session on the financing of HIV programmes yielded important results about the long-term costs and health impacts of continued Global Fund financing of ART. John Stover, from the Futures Group, presented the findings of a model on the future financing required for Global Fund-supported cohorts http://www.aidsmap.com/The-business-of-public-health-new-research-on-financing-of-HIV-programmes/page/1495585/ Epidemiology HIV treatment Vienna 2010 Rebecca Hodes http://www.aidsmap.com/page/1495585/ Tue, 27 Jul 2010 14:50:00 GMT South Africa’s campaign to test 15 million people for HIV in one year risks being implemented in a way that undermines people’s human rights, the activist Mark Heywood told the Eighteenth International AIDS Conference in Vienna last Thursday. Incidents of coercive testing have been recorded but the lack of effective monitoring procedures means that it’s impossible http://www.aidsmap.com/Mass-testing-campaign-unjustified-if-people-fail-to-receive-treatment-activist-argues/page/1496528/ Kenya Nigeria South Africa Testing policies and guidelines Vienna 2010 Roger Pebody http://www.aidsmap.com/page/1496528/ Tue, 27 Jul 2010 14:20:00 GMT Combination antiretroviral regimens containing atazanavir (Reyataz) plus drugs from two newer classes – the integrase inhibitor raltegravir (Isentress) and the CCR5 antagonist maraviroc (Celsentri) – demonstrated promising anti-HIV activity, but presented some concerns related to side-effects and drug resistance, according to two studies reported at a late-breaker session at the Eighteenth International AIDS Conference last week in http://www.aidsmap.com/Good-results-seen-with-NRTI-sparing-regimens-of-atazanavir-plus-newer-drug-classes/page/1497292/ HIV treatment New and experimental treatments Vienna 2010 Liz Highleyman http://www.aidsmap.com/page/1497292/ Mon, 26 Jul 2010 19:20:00 GMT People who had a low CD4 cell count in the past remain at greater risk for HIV-related neurocognitive impairment even after they start antiretroviral therapy and their immune status improves, participants heard in a late-breaker presentation at the Eighteenth International AIDS Conference last week in Vienna. Neurocognitive problems among people with HIV – ranging from mild http://www.aidsmap.com/Neurocognitive-impairment-linked-to-prior-low-CD4-cell-count-even-if-on-current-suppressive-HIV-treatment/page/1497294/ CD4 count Neurological and cognitive problems Starting treatment Vienna 2010 Liz Highleyman http://www.aidsmap.com/page/1497294/ Mon, 26 Jul 2010 19:20:00 GMT An analysis of transmission patterns in Lilongwe, Malawi shows that even if a highly effective HIV prevention intervention could reach 75% of people in chronic infection, it would never eliminate the HIV epidemic there. As a result, interventions that reduce transmission during early infection will also be required, Kimberly Powers told a late-breaker session http://www.aidsmap.com/Prevention-strategies-need-to-target-both-early-and-chronic-HIV-infection/page/1497220/ Epidemiology and behaviour Malawi Vienna 2010 Roger Pebody http://www.aidsmap.com/page/1497220/ Mon, 26 Jul 2010 16:30:00 GMT Starting antiretroviral therapy with a CD4 cell count between 350 and 500 cells/mm3 reduces the likelihood of HIV disease progression and death relative to initiation below 350 cells/mm3, according to findings from the large CASCADE study presented on Thursday at the Eighteenth International AIDS Conference in Vienna. Starting treatment with more than 500 cells/mm3 did http://www.aidsmap.com/CASCADE-analysis-finds-antiretroviral-treatment-benefits-are-evident-below-CD4-count-of-500-uncertain-above-this-level/page/1496057/ Starting treatment Treatment guidelines Vienna 2010 Liz Highleyman http://www.aidsmap.com/page/1496057/ Fri, 23 Jul 2010 14:40:00 GMT